Current role for cytoreduction and HIPEC for gastric cancer with peritoneal disease

Gastric cancer (GC) is an aggressive malignancy with a high burden of peritoneal disease. Evidence regarding the use of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) to improve outcomes has been growing. However, given multiple limitations, there remains a lack of...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Hamza, Johnston, Fabian M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322542/
https://www.ncbi.nlm.nih.gov/pubmed/35481913
http://dx.doi.org/10.1002/jso.26894
_version_ 1784756330498621440
author Khan, Hamza
Johnston, Fabian M.
author_facet Khan, Hamza
Johnston, Fabian M.
author_sort Khan, Hamza
collection PubMed
description Gastric cancer (GC) is an aggressive malignancy with a high burden of peritoneal disease. Evidence regarding the use of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) to improve outcomes has been growing. However, given multiple limitations, there remains a lack of international consensus regarding the optimal treatment paradigm. This review article discusses the burden of peritoneal disease in GC patients and the role of CRS + HIPEC in all treatment intents—curative, prophylactic, and palliative.
format Online
Article
Text
id pubmed-9322542
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93225422022-07-30 Current role for cytoreduction and HIPEC for gastric cancer with peritoneal disease Khan, Hamza Johnston, Fabian M. J Surg Oncol Review Articles Gastric cancer (GC) is an aggressive malignancy with a high burden of peritoneal disease. Evidence regarding the use of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) to improve outcomes has been growing. However, given multiple limitations, there remains a lack of international consensus regarding the optimal treatment paradigm. This review article discusses the burden of peritoneal disease in GC patients and the role of CRS + HIPEC in all treatment intents—curative, prophylactic, and palliative. John Wiley and Sons Inc. 2022-04-28 2022-06 /pmc/articles/PMC9322542/ /pubmed/35481913 http://dx.doi.org/10.1002/jso.26894 Text en © 2022 The Authors. Journal of Surgical Oncology published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Review Articles
Khan, Hamza
Johnston, Fabian M.
Current role for cytoreduction and HIPEC for gastric cancer with peritoneal disease
title Current role for cytoreduction and HIPEC for gastric cancer with peritoneal disease
title_full Current role for cytoreduction and HIPEC for gastric cancer with peritoneal disease
title_fullStr Current role for cytoreduction and HIPEC for gastric cancer with peritoneal disease
title_full_unstemmed Current role for cytoreduction and HIPEC for gastric cancer with peritoneal disease
title_short Current role for cytoreduction and HIPEC for gastric cancer with peritoneal disease
title_sort current role for cytoreduction and hipec for gastric cancer with peritoneal disease
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322542/
https://www.ncbi.nlm.nih.gov/pubmed/35481913
http://dx.doi.org/10.1002/jso.26894
work_keys_str_mv AT khanhamza currentroleforcytoreductionandhipecforgastriccancerwithperitonealdisease
AT johnstonfabianm currentroleforcytoreductionandhipecforgastriccancerwithperitonealdisease

Ejemplares similares